Responses to the public consultation on the concept paper on the detailed rules for a unique identifier for medicinal product for human use

Directive 2011/62/EU to fight against falsified medicines introduces obligatory 'safety features' to allow, inter alia, verification of the authenticity of medicinal products for human use ('unique identifier'). The Directive places the Commission under an obligation to adopt delegated acts setting out the details relating to inter alia the unique identifier. The enclosed concept paperpdf(93 KB) has been launched for public consultation until 27 April 2012 with a view to preparing both the impact assessment and the delegated act

Below are the public responses to the above mentioned concept paper.

Some contributors requested their responses not to be made public.